Journal
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Volume 36, Issue 1, Pages 103-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2015.08.010
Keywords
Allergic rhinitis; Allergen immunotherapy; Vaccine modification
Categories
Ask authors/readers for more resources
There is a need for newer therapeutic agents that improve the safety of allergen immunotherapy, provide ease of delivery to patients that fosters compliance and allows access to a greater proportion of the allergic population who could benefit from this disease-modifying treatment, and achieve an acceptable therapeutic benefit for patients committing to the treatment. The advances in sublingual allergen immunotherapy are encouraging, as this offers patients a noninjectable form of treatment of inhalant allergies. The continued research and development of the novel therapeutic constructs discussed in this article holds the promise of accomplishing the aforementioned goals in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available